Public Hearings Second stakeholder forum on the implementation of - - PowerPoint PPT Presentation

public hearings
SMART_READER_LITE
LIVE PREVIEW

Public Hearings Second stakeholder forum on the implementation of - - PowerPoint PPT Presentation

Public Hearings Second stakeholder forum on the implementation of the new Pharmacovigilance legislation, 17 June 2011 Presented by: Monika Benstetter (European Medicines Agency) and Doris Stenver (Danish Medicines Agency) An agency of the


slide-1
SLIDE 1

An agency of the European Union

Public Hearings

Second stakeholder forum on the implementation of the new Pharmacovigilance legislation, 17 June 2011

Presented by: Monika Benstetter (European Medicines Agency) and Doris Stenver (Danish Medicines Agency)

slide-2
SLIDE 2

Public hearings 1

Purpose

  • Respond to public demands for more transparency
  • f the scientific review process
  • Give stakeholders a voice by enabling their

participation in the scientific deliberation process

  • Help to build trust in the Agency by opening up its

procedures to the public

  • Give access to public testimony or comment

regarding therapeutic effects and clinical practice of medicines under investigation

slide-3
SLIDE 3

Public hearings 2

Legal basis

Article 107j of Directive 2001/ 83/ EU as amended “Where the urgency of the matter permits, the Pharmacovigilance Risk Assessment Committee may hold public hearings, where it considers that this is appropriate on justified grounds particularly with regard to the extent and seriousness of the safety concern. The hearings shall be held in accordance with the modalities specified by the Agency and shall be announced by means of the European medicines web-portal. The announcement shall specify the modalities of participation. In the public hearing due regard shall be given to the therapeutic effect of the medicinal product.”

slide-4
SLIDE 4

Public hearings 3

What the EMA wants to achieve

A participatory process that allows transparent interaction w ith stakeholders and in which we aim to obtain inform ation from the stakeholders that adds value to the assessment of medicines.

slide-5
SLIDE 5

Public hearings 4

How do we get there?

  • Stepwise implementation (Start with Art. 107

procedures)

  • Learning from others (e.g. European Commission,

FDA, other health authorities, other scientific bodies)

  • Ongoing review and improvement of our process
slide-6
SLIDE 6

Public hearings 5

Deliverables

  • Criteria when to hold public hearings
  • Rules of procedure on the organisation and conduct
  • f public hearings
  • A process for participation
slide-7
SLIDE 7

Public hearings 6

Open questions

  • Participation in the public hearing
  • Advance notification
  • Language regime
slide-8
SLIDE 8

Public hearings 7

Open questions

  • Access to hearing
  • Use of broadcasting technology
  • Requests for non-public hearings
  • Follow-up to the hearing
slide-9
SLIDE 9

Public hearings 8

Thank you!

Your ideas